Navigation Links
Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results
Date:2/27/2009

transaction will not be completed, or if completed, not completed on a timely basis; the possibility that the acquisition of Indevus is not complementary to Endo; the potential that market segment growth will not follow historical patterns; general industry conditions and competition; business and economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, particularly the discussion under the caption "Item 1A, RISK FACTORS" in our annual report on Form 10-K/A for the year ended December 31, 2007, which was filed with the Securities and Exchange Commission on April 29, 2008. The forward-looking statements in this press release and on the related conference call are qualified by these risk factors. These are factors that, individually or in the aggregate, we think could cause our actual results to differ materially from expected and historical results. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

(Tables Attached)

The following tables present Endo's unaudited net sales for the three months and year ended December 31, 2008 and December 31, 2007:

                     Endo Pharmaceuticals Holdings Inc.
                           Net Sales (unaudited)
                              (in thousands)

                                             
'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Endo Pharmaceuticals Returns Product Rights to TRANSDUR(TM)-Sufentanil to DURECT
2. Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results and Highlights
3. Arbor Pharmaceuticals Announces the Launch of XYLAREX(TM) - A New Nonantibiotic Product for the Dietary Management of Recurrent Ear Infections in Children
4. Endo Pharmaceuticals Appoints William Montague to Board of Directors
5. Access Pharmaceuticals Closes Acquisition of MacroChem Corp.
6. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results
7. Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
8. Transdel Pharmaceuticals, Inc. Featured on National Broadcast Television
9. Update: Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2008 Financial Results
10. Vanda Pharmaceuticals Responds to Announcement and Filing by a Group Led by Tang Capital Partners, LP
11. Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... UWDress.com, one of the most famous dress ... of 2014 floor length bridesmaid dresses . Additionally, ... items. According to the company’s marketing specialist, all its ... rate (up to 60 percent off) before September 10. ... special neckline: strapless, one-shoulder, bateau and more. The main ...
(Date:8/29/2014)... As reported by GantDaily.com in the article ... , Outbreaks (8/20), the National Institute on Drug Abuse is ... trends by turning to social media. As NIDA currently relies ... also working with the University of Maryland to create a ... which will be funded by the National Institute of Health. ...
(Date:8/29/2014)... August 30, 2014 Market Research ... 2009-2019 is a professional and in-depth market survey ... report firstly reviews the basic information of Glass ... The report then explores global and China’s top ... capacity, Production value, and market share etc. , ...
(Date:8/29/2014)... Angeles, CA (PRWEB) August 29, 2014 Dr. ... with late stages of hair loss achieve great results in ... the Facial Hair Transplant , an FUE method that ... recipient area. This method lets patients whose hair loss ... head. Facial Hair Transplant is a great alternative for those ...
(Date:8/29/2014)... -- Astronauts may be at heightened risk of ... systems, a new study suggests. That could be ... the moon and Mars undertaken in the future, because ... be dangerous, NASA researchers say. They found that ... International Space Station crew members remains relatively unchanged during ...
Breaking Medicine News(10 mins):Health News:2014 Floor Length Bridesmaid Dresses for Sale at UWDress.com 2Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 2Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Advanced Hair Loss Patients Can Now Qualify for Hair Transplants Using Facial Donor Hair 2Health News:Spaceflight Might Weaken Astronauts' Immune Systems 2
... , BOYNTON BEACH, Fla. , Feb. ... of this year,s US Open Men,s and Women,s tennis tournament ... http://www.newscom.com/cgi-bin/prnh/20100209/DC52484 ) , (Logo: http://www.newscom.com/cgi-bin/prnh/20100120/DC41252LOGO-b ) , Would you ... Golf tournament, complete with airfare and accommodations? , Would you ...
... INDIANAPOLIS -- In the first large-scale epidemiological study of ... researchers from the Indiana University School of Medicine and ... 2010 issue of The Journal of Trauma Injury, ... and opportunities for prevention of these injuries. Nearly ...
... Medical Center are offering pediatric patients diagnosed with chronic ... negative side effects like nausea, fatigue, and vomiting caused ... confluence of Chinese and Western medicine at Rush Children,s ... document how acupuncture might help in reducing pain in ...
... ... Collection Manager™ increases patient safety through accuracy and timeliness , ... (PRWEB) February 9, 2010 ... outreach solutions, announced today that the University of Virginia Health System Medical Laboratories, ...
... D begins in the womb, expert says, , TUESDAY, Feb. ... lots of milk and have a high dietary intake of ... developing multiple sclerosis later in life, researchers say. , The ... about their experiences and diet during pregnancy. The nurses were ...
... , Consumer Watchdog Also Warns Against Insurer-favored ,Cost Solution,: ... Apartment" , WASHINGTON , Feb. 9 ... its premium hikes of up to 39% in California , ... House and an investigation by California ,s insurance commissioner, federal ...
Cached Medicine News:Health News:Would You Like to Own a Thriller Album Autographed by Michael Jackson Himself? 2Health News:Watch your step: Elevator-related injuries and older adults 2Health News:Watch your step: Elevator-related injuries and older adults 3Health News:Young patients with chronic illnesses find relief in acupuncture 2Health News:University of Virginia Health System Medical Laboratories Selects Sunquest's Specimen Collection Solution 2Health News:University of Virginia Health System Medical Laboratories Selects Sunquest's Specimen Collection Solution 3Health News:Drinking Milk While Pregnant May Lower Kids' MS Risk 2Health News:Blue Cross Claim That 39% Premium Hikes Due Only to 'Escalating Cost of Health Care' Trigger Calls for Regulation of Rates 2Health News:Blue Cross Claim That 39% Premium Hikes Due Only to 'Escalating Cost of Health Care' Trigger Calls for Regulation of Rates 3
(Date:8/29/2014)... N.C. , Aug. 29, 2014 The ... of regulatory and marketplace changes. CI leaders who adjust ... In a new Best Practices, LLC study ... of actionable insights, including: - Use secondary ... than primary research - Internal staff who ...
(Date:8/29/2014)... MENLO PARK, Calif. , Aug. 29, 2014 /PRNewswire/ ... Medina Medical as CEO and member of the Board ... three decades of medical device development and commercialization experience, ... Medical,s field. Mr. Engelson previously served as a Partner ... served as President and CEO of two Foundry start-ups. ...
(Date:8/29/2014)... 29, 2014 Research and Markets  has announced ... Insight 2014" report to their offering. ... one of the largest segments of pharmaceuticals industry. The numbers ... the available therapies were unable to meet the market requirements. ... for CNS disorder, especially over the past two decades. The ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2US CNS Disorders Drug Pipeline Insight 2014 2
... 23 SurgiCount Medical, the wholly-owned operating subsidiary ... PSTX ), announced that results of ... Clinic on their multi-year effort to reduce retained ... two upcoming conferences.  The research and related discussion ...
... Agreement to Develop and... -- ABBOTT PARK, Ill. and IRVING, Texas, Sept. 23 ... ... --> ... s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
Cached Medicine Technology:Mayo Clinic Research on SurgiCount To Be Presented at Conferences 2Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 2Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 3Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 4Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 5Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 6Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 7Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 8Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 9
... RAM Scientifics SAFE-T-FILL Capillary Blood Collection ... systems. Available for a wide range of ... with a capillary tube, attached cap and ... action to draw the blood into the ...
... RAM Scientifics SAFE-T-FILL Capillary Blood Collection Tubes ... Available for a wide range of applications, ... a capillary tube, attached cap and a ... to draw the blood into the micro ...
... Toxoplasmosis has progressed from the ... test to immunoflourescence, latex and ... In addition to Toxo IgG ... Toxo IgM immunocapture and indirect ...
... an enzyme immunoassay test in a microwell format. ... incubation. The results are objective and normalized ... The Bio-Rad Measles IgG test is intended for ... antibodies to measles virus in human serum by ...
Medicine Products: